| |
| Device | Ventana PD-L1 (SP142) Assay |
| Generic Name | Immunohistochemistry assay, antibody, programmed death-ligand 1 |
| Applicant | Ventana Medical Systems, Inc. 1910 E. Innovation Park Dr. Tucson, AZ 85755 |
| PMA Number | P160002 |
| Supplement Number | S012 |
| Date Received | 01/21/2020 |
| Decision Date | 05/18/2020 |
| Product Code |
PLS |
| Advisory Committee |
Pathology |
| Clinical Trials | NCT02409342
|
| Supplement Type | Normal 180 Day Track |
| Supplement Reason | Labeling Change - Indications/instructions/shelf life/tradename |
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement Approval of the VENTANA PD-L1 (SP142) Assay as a companion diagnostic for identifying patients with non-small cell lung carcinoma (NSCLC) with PD-L1 expression in TC >= 50% or IC >= 10% for treatment with TECENTRIQ based upon the IMpower110 clinical study. |
| Labeling | Labeling
|